Shandong Oriental Ocean Sci-Tech Co Ltd

Shandong Oriental Ocean Sci-Tech Co., Ltd. announced that its wholly owned subsidiary Avioq Bio-Tech Co., Ltd. has obtained a medical device registration certificate issued by the Shandong Medical Products Administration for its self-developed Scavenger Receptor-A Assay Kit (Magnetic Particle Chemiluminescence Method). The registration certificate number is Lu Xie Zhu Zhun 20262400352, valid from August 31, 2026 to August 30, 2031. The product is used for in vitro qualitative determination of scavenger receptor-A in human serum and plasma. The company stated that the approved launch of this product will enrich the subsidiary's product line in the clinical testing field, but Avioq Bio-Tech Co., Ltd. has had a relatively small impact on the company's performance this year, and the product has not yet been put into production. Actual sales are affected by multiple factors, and the specific impact on future performance cannot be predicted at this time.

Shandong Oriental Ocean Sci-Tech Co., Ltd. wholly-owned subsidiary Avioq Bio-Tech Co., Ltd. has independently developed a neutrophil gelatinase-associated lipocalin test kit using fluorescence immunochromatography, and has obtained a medical device registration certificate from the Shandong Medical Products Administration. The registration certificate number is Lu Xie Zhu Zhun 20262400300, valid from July 23, 2026 to July 22, 2031. The product is used for in vitro quantitative determination of neutrophil gelatinase-associated lipocalin levels in human whole blood and serum. Previously, on July 28, 2026, the company announced the approval of a magnetic particle chemiluminescence kit from the same series. This latest certification further enriches the subsidiary's clinical testing product line. The company stated that the subsidiary's impact on this year's performance is minimal, the product has not yet been put into production, and actual sales are subject to multiple factors such as market expansion and demand. It is currently unable to predict the specific impact on future performance.

Oriental Ocean's wholly-owned subsidiary, Avioq Bio-Tech, has recently obtained a medical device registration certificate for a neutrophil gelatinase-associated lipocalin assay kit. The product uses a magnetic particle chemiluminescence method for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin levels in human serum. The registration is valid from July 23, 2026, to July 22, 2031. This certification will enrich the company's product line in the clinical testing field, though the product has not yet entered production. In the first quarter of 2026, Oriental Ocean achieved revenue of 78.37 million yuan and a net loss attributable to the parent company of 11.27 million yuan.